Case analysis of a patient with osimertinib-induced interstitial pneumonia who re-used EGFR-TKI therapy
- VernacularTitle:1例奥希替尼致间质性肺炎患者再用EGFR-TKI治疗的病例分析
- Author:
Yongbang CHEN
1
,
2
;
Ning WAN
1
;
Bing WANG
1
,
3
;
Lijun PENG
4
;
Ning YANG
4
;
Weibin XIAO
1
;
Fei XIE
1
;
Jianping ZHANG
2
;
Bo JI
1
Author Information
1. Dept. of Clinical Pharmacy，General Hospital of Southern Theatre Command of PLA，Guangzhou 510010，China
2. College of Pharmacy，Jinan University，Guangzhou 511436，China
3. School of Pharmaceutical Sciences，Southern Medical University，Guangzhou 510515，China
4. Dept. of Oncology，General Hospital of Southern Theatre Command of PLA，Guangzhou 510010，China
- Publication Type:Journal Article
- Keywords:
osimertinib;
interstitial pneumonia;
epidermal
- From:
China Pharmacy
2023;34(5):595-599
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the way to re-use epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKI） in patients with EGFR-TKI-induced interstitial pneumonia （IP）， using osimertinib as an example. METHODS The IP treatment regimen and re-use of EGFR-TKI regimen in a patient who developed IP after the use of osimertinib were analyzed. And a literature review was made by combining the characteristics of the cases which reported in the literature and the characteristics of this case. RESULTS The patient’s IP symptoms due to treatment with osimertinib had resolved after treatment. The patient’s IP symptoms also did not worsen after using almonertinib in combination with hormones as re-use of EGFR-TKI regimen. However， almonertinib was discontinued as the patient experienced disease progression. The adverse reactions of IP needed to be dealt with in time， the EGFR-TKI should be discontinued and symptomatic treatment should be given. CONCLUSIONS EGFR-TKI targeted therapy could be re-selected by replacing EGFR-TKI， adjusting the dose of EGFR-TKI， and using hormones in combination. EGFR-TKI-induced adverse drug reactions of IP are rare， but need to be observed closely. If other EGFR-TKI is used， close monitoring of adverse reactions and curative effects are also required in order to adjust the patient’s treatment plan in time.
